Stocktoria
Immix Biopharma, Inc. IMMX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-12-16
Immix Biopharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $16.3M | $11.3M | $8.7M | $4.2M | $126,527 |
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | -$1.4M |
| Interest expense | — | — | — | $497 | $179,853 |
| Income tax | $37,724 | $41,037 | $26,415 | $10,268 | $6,013 |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | -$24.4M |
| EPS (diluted) | $-0.89 | $-0.76 | $-0.89 | $-0.59 | — |
| Operating cash flow | -$23.9M | -$14.6M | -$11.4M | -$7.4M | -$1.6M |
| Free cash flow | -$24.7M | -$15.8M | -$11.4M | — | -$1.6M |
| Cash & equivalents | $93.9M | $17.7M | $17.5M | $13.4M | $17.6M |
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202,039 |
| Shareholders' equity | $93.8M | $13.3M | $16.4M | $13.2M | $18.0M |
Source: SEC EDGAR filings · CIK 0001873835 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.